JLJacek J. Litewka

Jacek J. Litewka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jacek J. Litewka has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Novel 1,3,5-triazine-based TRPA1 activators alleviate pro-fibrotic response in human lung fibroblasts

    by Natalia Janikowska, Grażyna Chłoń-Rzepa, Paweł Żmudzki, Paweł E. Ferdek, Jacek J. Litewka, Alicja Gawalska, Paulina Koczurkiewicz-Adamczyk, Aleksandra Łapa, Elżbieta PęKala, Katarzyna Wójcik-Pszczoła

  • Open Access

    BCL2 inhibition in acute and chronic pancreatitis — is there a therapeutic perspective?

    by Jacek J. Litewka, Monika A. Jakubowska, Wei Huang, Pawel E. Ferdek

    Necrotic death of pancreatic acinar cells leads to premature activation of digestive enzymes and is a central driver of inflammation in acute pancreatitis (AP). In contrast, apoptosis is a non-lytic, regulated form of cell death that prevents the release of intracellular content and is therefore considered less damaging. The induction of the intrinsic apoptotic pathway is tightly regulated by the balance between pro- and anti-apoptotic members of the BCL2 protein family. Pharmacological inhibitors of anti-apoptotic BCL2 proteins – BH3 mimetics – have thus emerged as tools to therapeutically shift cell fate from necrosis to apoptosis. Early-generation BH3 mimetics such as HA14-1 and BH3I-2′ used to validate this concept were hindered by limited potency and significant off-target effects, including disruption of calcium homeostasis. More selective and potent second-generation agents – particularly Navitoclax (ABT-263) and Venetoclax (ABT-199) – have overcome these limitations, with Venetoclax now approved for clinical use in haematological malignancies. Here, we explore the therapeutic potential of BCL2 inhibitors in pancreatic diseases, with a focus on AP and a comparison to chronic pancreatitis (CP). In AP models, BCL2 inhibition – especially with Venetoclax – redirects cell death from necrosis to apoptosis, preserving intracellular ATP, attenuating aberrant Ca 2+ signalling, and reducing tissue damage and inflammation, without overt toxicity to healthy acinar cells in the absence of injurious stimuli. In contrast, in CP, a disease marked by fibrosis and prevailing apoptotic loss of parenchyma, BCL2 inhibition provides no benefit and may exacerbate acinar atrophy and fibrogenesis. We discuss the mechanistic basis of these divergent effects, including the role of BCL2 proteins in cell death regulation and calcium dynamics. Finally, we highlight future directions, including the rationale for clinical testing of Venetoclax in AP, and discuss cautionary considerations for its use in CP, particularly in patients with coexisting conditions such as leukaemia, who may already be receiving BH3 mimetics.

  • Open Access

    Repurposing BCL2 inhibitors: Venetoclax protects against acinar cell necrosis in acute pancreatitis by promoting apoptosis

    by Jacek J. Litewka, Mateusz D. Szopa, Katarzyna Fryt, Monika A. Jakubowska, Urszula Jankowska, Bozena Skupien-Rabian, Karolina Hajduk, Ewa Werner, Kinga B. Stopa, Agnieszka A. Kusiak, et al.

    Acute pancreatitis (AP), a severe inflammatory disorder of the pancreas, lacks effective pharmacological treatment. The disease is primarily driven by necrosis of pancreatic acinar cells (PACs), which intensifies inflammation and organ injury. This study explores the potential of BCL2 inhibitors, specifically Navitoclax and Venetoclax, to shift cell death pathways from necrosis to apoptosis and thereby mitigate disease severity. Ex vivo models using cerulein or ethanol/palmitoleic acid (EtOH/POA) showed that both inhibitors significantly reduced necrosis, increased apoptosis, and improved PAC viability and ATP levels. In mouse models of AP, both drugs promoted apoptosis and decreased tissue necrosis, with Venetoclax showing superior efficacy and safety. Venetoclax markedly reduced disease severity in two AP models without affecting healthy tissue or inducing thrombocytopenia. In contrast, Navitoclax caused apoptosis even in healthy tissue and triggered thrombocytopenia. Additionally, both drugs attenuated pathological Ca2+ responses in PACs and upregulated the expression of Ca²⁺-binding proteins S100A8/A9 and the chemokine CCL8. The latter may mediate enhanced apoptotic clearance and limit secondary necrosis, supporting the therapeutic shift from necrosis to apoptosis. Proteomic analyses revealed extensive drug-induced remodeling. In the short-term AP model, both inhibitors altered expression of proteins linked to intracellular compartments and extracellular signaling, reflecting cellular adaptation. In CP, Navitoclax upregulated ECM and lysosomal proteins while downregulating ribosomal components—indicating intensified fibrosis and suppressed protein synthesis. Venetoclax had milder effects and did not worsen fibrosis. Despite Navitoclax’s efficacy toward activated pancreatic stellate cells in vitro, it exacerbated fibrosis and tissue atrophy in CP in vivo, likely due to ongoing parenchymal damage and stellate cell activation. Together, these findings demonstrate that selective BCL2 inhibition with Venetoclax promotes apoptosis, reduces necrosis, and improves outcomes in AP, supporting its repurposing as a therapeutic strategy. However, BCL2 inhibition does not benefit CP and may aggravate fibrosis, underscoring the need for context-specific approaches.


  • Open Access

    Polyethylene Glycols Stimulate Ca2+ Signaling, Cytokine Production, and the Formation of Neutrophil Extracellular Traps

    by Alicja Hinz, Sylwia Stankiewicz, Jacek Litewka, Paweł Ferdek, Maja Sochalska, Monika Bzowska

    Purpose: Given the increased use of polyethylene glycol (PEG) in refining the therapeutic activity of medicines, our research focuses on explaining the potential mechanism of immune reactions associated with this polymer. We aim to investigate the interaction of different types of PEG with mouse and human immune cells, thereby contributing to understanding PEG interactions with the immune system and verifying the proinflammatory activity of the tested polymers. Patients and Methods: Mouse macrophage and neutrophil cell lines, human peripheral blood mononuclear cells, and polymorphonuclear cells isolated from healthy donors were exposed to various PEGs. ROS, NO, and cytokine production were analyzed using fluorescence intensity, absorbance, or cytometric measurements. Toll-like receptor (TLR) signaling was verified using HEK-bluereporter cell lines. Finally, neutrophil trap formation was studied using immunofluorescence labeling, and calcium imaging was performed using a Ca2+-sensitive indicator and fluorescence microscope. Results: Our findings show that specific PEG and mPEG are not toxic to tested mouse and human cells. However, they exert proinflammatory activity against human immune cells, as evidenced by the increased secretion of proinflammatory cytokines, such as IFN-a2, IFN-gamma, TNF-alpha, MCP-1, IL-8, IL-17A, and IL-23. This phenomenon is independent of PEG signaling via TLR. Additionally, mPEG10 induced the formation of neutrophil extracellular traps and intracellular calcium signaling. Conclusion: Our finding suggests that some PEG types have proinflammatory activity against human immune cells, manifesting in the upregulated production of cytokines and neutrophils trap releasing.